Selinexor, also known as KPT-330, is an orally bioavailable, potent and selective XPO1/CRM1 Inhibitor. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Selinexor potentiates the antitumor activity of gemcitabine in human pancreatic cancer through inhibition of tumor growth, depletion of the antiapoptotic proteins, and induction of apoptosis. Selinexor has strong activity against primary AML cells while sparing normal stem and progenitor cells.
Muthusamy, Anantha Rajmohan; Kanniah, Sundara Lakshmi; Ravi, Akash; Das, Tonmoy Chitta; Chemate, Rajendra Popat; Singh, Anil Kumar; Wagh, Yogesh Dhananjay. Novel crystalline forms of selinexor and process for their preparation. Assignee Watson Laboratories Inc., USA. WO 2018129227. (2018).
Chen, Xinying; Xu, Liang; Liu, Wenzhong. Synthesis method of selinexor bulk pharmaceutical. Assignee Guangzhou Wenhao Biotechnology Co., Ltd., Peop. Rep. China. CN 106831731. (2017).
Sandanayaka, Vincent P.; Shacham, Sharon; McCauley, Dilara; Shechter, Sharon. Preparation of hydrazide containing nuclear transport modulators and uses thereof. Assignee Karyopharm Therapeutics, Inc., USA. WO 2013019548. (2013).
